Dengue vaccine more risky for people without prior infection – Sanofi

A new analysis of Manila - clinical data in the Philippines shows that Sanofi pasteur 's dengue vaccine brings more risk to those who are not infected before vaccination

After a new analysis of the clinical data for 6 years, sanofi announced the news in a statement issued Wednesday, 29th November.

"This analysis has confirmed that ensenza has a sustained protective effect against the dengue fever of previously infected people, but for those who have never been infected with dengue virus before, the analysis is long-term There may be more serious vaccination cases of illness, then dengue fever infection, "sanofi said

Pharmaceutical companies will now recommend local regulators to update the label of the vaccine. For those who have not previously been infected with dengue, going to France is no longer recommended.

"Vaccination should be recommended only if the potential benefits outweigh the potential risk (in countries with high dengue burden). For those who have not previously been infected with dengue virus, vaccination It should not be recommended, "sanofi said.

Sanofi announced a major blow to the country (including the Philippines) that uses Dunkasha for domestic vaccination programs and allows commercial sales of vaccines

Vaccine marketing was approved in 11 countries. Others are Brazil, Costa Rica, El Salvador, Guatemala, Mexico, Paraguay, Peru, Indonesia, Singapore, Thailand

The Ministry of Health in the Philippines (DOH) began implementing the dengue fever vaccination program in 2016. Initially, in the central part of Luzon Island, four hundred thousand students (at least 9 years old) of the hundreds of thousands of people in Karaburzon and the metropolitan area were vaccinated.

Health officials previously cited concerns about the risk of vaccine use, quoting the recommendations of the World Health Organization (WHO) expert committee recommending the world's first dengue vaccine in areas with a high proportion of diseases mediated by mosquitoes I tried to reduce it.

Francisco Duque III Minister of Health told Rappler that the DOH Technical Service office is already talking about sanofi consulting. They also consult independent experts

However, Duke assured the people that "the safety of our children is very important." He said that once sanofi vaccination talks are decided, this will be the main consideration of the Ministry of Health.

Last year, a warning was issued to the Ministry of Health's "hurry" dengue vaccination program and urged Congress to investigate the plan.

Dr. Anthony Leachon, an independent director of the Philippine health insurance company and former president of the Philippine Doctor Foundation, said large vaccinations are "unusual" with the approval of vaccine regulators.

Dr. Antonio Dans, Chairman of the Philippine General Medical Association, also warned that "antibody dependent increase" may initially reduce the number of dengue cases but a phenomenon that may increase the severity of the disease . - Rappler.com

Last month, Sanofi Pasteur, a division of the French pharmaceutical company sanofi, withdrew the experimental dengue fever vaccine against dengue. Complications in patients who have never experienced dengue. So, two years later, there was a problem with the plan to vaccinate children with dengue fever. Consultancy by the Philippine Department of Health (DOH) physician and pharmacologist - the Advisory Committee Executive Committee (FEC) made a series of recommendations at the beginning of the program. None of these are accepted, and the program continues immunization for 830,000 children. They warned that vaccine safety and cost effectiveness should not be treated with caution as it is not decided in the recommendation.

Pharmaceutical company Sanofi Pasteur announced that Filipinos (primarily school-age children) may be at greater risk of disease, vaccinated people have not previously been dengue-infected did. On December 4, 2017, sanofi denied having turned Filipino into "guinea pig" and explained that the vaccine program was implemented by the Ministry of Health, not sanofi. Dr. Ruby Dizon of Sanofi Medical Director said that dengue vaccination does not cause "serious dengue fever". Senator JV Ejercito, the chairman of the Senate Health Population Committee, is trying to determine if there is a violation of vaccine purchase by January 2018. Senator Risa Hontiveros asked the government to respond to the health risks of the vaccine. Philippine Food and Drug Administration orders sanofi to stop dispatching Devasha to the country